Cargando…

AKT can modulate the in vitro response of HNSCC cells to irreversible EGFR inhibitors

Epidermal growth factor receptor (EGFR) is overexpressed in up to 90% of head and neck squamous cell carcinoma (HNSCC) tumors. Cetuximab is the first targeted (anti-EGFR) therapy approved for the treatment of HNSCC patients. However, its efficacy is limited due to primary and secondary resistance, a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Silva-Oliveira, Renato José, Melendez, Matias, Martinho, Olga, Zanon, Maicon F., de Souza Viana, Luciano, Carvalho, André Lopes, Reis, Rui Manuel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581110/ https://www.ncbi.nlm.nih.gov/pubmed/28881811 http://dx.doi.org/10.18632/oncotarget.18395

Ejemplares similares

Hypoxia Mediates Differential Response to Anti-EGFR Therapy in HNSCC Cells
por: Wiechec, Emilia, et al.
Publicado: (2017)

TIMP3 and CCNA1 hypermethylation in HNSCC is associated with an increased incidence of second primary tumors
por: Rettori, Marianna Marconato, et al.
Publicado: (2013)

Radiosensitization of HNSCC cells by EGFR inhibition depends on the induction of cell cycle arrests
por: Kriegs, Malte, et al.
Publicado: (2016)

Overcoming resistance to EGFR monotherapy in HNSCC by identification and inhibition of individualized cancer processes
por: Jubran, Maria R., et al.
Publicado: (2022)

miR‐9 modulates and predicts the response to radiotherapy and EGFR inhibition in HNSCC
por: Citron, Francesca, et al.
Publicado: (2021)

Adaptive ERK signalling activation in response to therapy and in silico prognostic evaluation of EGFR-MAPK in HNSCC
por: Rong, Chao, et al.
Publicado: (2020)

Phytochemicals targeting epidermal growth factor receptor (EGFR) for the prevention and treatment of HNSCC: A review
por: Li, Shaling, et al.
Publicado: (2023)

Constitutive or Induced HIF-2 Addiction is Involved in Resistance to Anti-EGFR Treatment and Radiation Therapy in HNSCC
por: Coliat, Pierre, et al.
Publicado: (2019)

Incidence and survival of HNSCC patients living with HIV compared with HIV-negative HNSCC patients
por: Haase, Katharina, et al.
Publicado: (2021)

PLAU and LAMC2 can predict a poor prognosis in patients with HNSCC
por: Guo, Zhi-chen, et al.
Publicado: (2023)

Grape Seed Proanthocyanidins Inhibit the Invasiveness of Human HNSCC Cells by Targeting EGFR and Reversing the Epithelial-To-Mesenchymal Transition
por: Sun, Qian, et al.
Publicado: (2012)

Interaction between hypoxia, AKT and HIF-1 signaling in HNSCC and NSCLC: implications for future treatment strategies
por: Stegeman, Hanneke, et al.
Publicado: (2016)

Retraction: Grape Seed Proanthocyanidins Inhibit the Invasiveness of Human HNSCC Cells by Targeting EGFR and Reversing the Epithelial-To-Mesenchymal Transition
Publicado: (2018)

Neuropilin-1 Expression Associates with Poor Prognosis in HNSCC and Elicits EGFR Activation upon CDDP-Induced Cytotoxic Stress
por: Napolitano, Virginia, et al.
Publicado: (2021)

Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors
por: Wagener-Ryczek, Svenja, et al.
Publicado: (2020)

Stochastic dynamics and irreversibility
por: Tomé, Tânia, et al.
Publicado: (2015)

Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A
por: Chiba, Masato, et al.
Publicado: (2017)

lncRNA in HNSCC: challenges and potential
por: Guglas, Kacper, et al.
Publicado: (2017)

HNSCC: Tumour Antigens and Their Targeting by Immunotherapy
por: von Witzleben, Adrian, et al.
Publicado: (2020)

NF-Y Subunits Overexpression in HNSCC
por: Bezzecchi, Eugenia, et al.
Publicado: (2021)

The Impact of YRNAs on HNSCC and HPV Infection
por: Guglas, Kacper, et al.
Publicado: (2023)

Construction and characterization of a new TRAIL soluble form, active at picomolar concentrations
por: Melendez, Matias Eliseo, et al.
Publicado: (2018)

Activation of Akt at T308 and S473 in alcohol, tobacco and HPV-induced HNSCC: is there evidence to support a prognostic or diagnostic role?
por: Islam, Mohammad R, et al.
Publicado: (2014)

Letter to the editor concerning first-line therapy with afatinib – an irreversible EGFR TKI and overall survival of NSCLC patients with EGFR gene mutations
por: Krawczyk, Paweł, et al.
Publicado: (2015)

The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients
por: Wu, Shang-Gin, et al.
Publicado: (2016)

Irreversible
Publicado: (2009)

HER Family Receptors are Important Theranostic Biomarkers for Cervical Cancer: Blocking Glucose Metabolism Enhances the Therapeutic Effect of HER Inhibitors
por: Martinho, Olga, et al.
Publicado: (2017)

CD73 is associated with poor prognosis in HNSCC
por: Ren, Zhen-Hu, et al.
Publicado: (2016)

Impact and Relevance of the Unfolded Protein Response in HNSCC
por: Pluquet, Olivier, et al.
Publicado: (2019)

Analyzing expression and phosphorylation of the EGF receptor in HNSCC
por: Kriegs, Malte, et al.
Publicado: (2019)

Review of biomarkers for response to immunotherapy in HNSCC microenvironment
por: Chen, Shaoshi, et al.
Publicado: (2023)

Discovery and characterization of a novel irreversible EGFR mutants selective and potent kinase inhibitor CHMFL-EGFR-26 with a distinct binding mode
por: Hu, Chen, et al.
Publicado: (2017)

ANO1 amplification and expression in HNSCC with a high propensity for future distant metastasis and its functions in HNSCC cell lines
por: Ayoub, C, et al.
Publicado: (2010)

Molecular characterization of EGFR, PDGFRA and VEGFR2 in cervical adenosquamous carcinoma
por: Longatto-Filho, Adhemar, et al.
Publicado: (2009)

MiR-21 as prognostic biomarker in head and neck squamous cell carcinoma patients undergoing an organ preservation protocol
por: Arantes, Lidia Maria Rebolho Batista, et al.
Publicado: (2016)

Tumor Ablation with Irreversible Electroporation
por: Al-Sakere, Bassim, et al.
Publicado: (2007)

Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells
por: Wu, Hong, et al.
Publicado: (2015)

Differentially expressed proteins in positive versus negative HNSCC lymph nodes
por: Vidotto, Alessandra, et al.
Publicado: (2018)

Secretory leukocyte protease inhibitor suppresses HPV E6-expressing HNSCC progression by mediating NF-κB and Akt pathways
por: Jin, Yu, et al.
Publicado: (2019)

Combined Inhibitions of Glycolysis and AKT/autophagy Can Overcome Resistance to EGFR-targeted Therapy of Lung Cancer
por: Ye, Mingtong, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_kgvk4tk2vjp0b4s4m1uhpu3r7n